Oncotelic Therapeutics, Inc.
OTLC
$0.047
$0.0024.44%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.31% | 42.76% | 62.60% | 90.72% | -182.66% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -29.07% | -59.54% | 0.92% | -86.07% | -91.18% |
| Total Other Non-Cash Items | -49.00% | -47.96% | -66.98% | -99.47% | 150.45% |
| Change in Net Operating Assets | 342.52% | 503.71% | -115.61% | -112.29% | -120.73% |
| Cash from Operations | 48.07% | 43.96% | 1.96% | -13.01% | -75.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -61.23% | -53.48% | 54.25% | 543.76% | 119.09% |
| Total Debt Repaid | -- | -- | -100.00% | -106.25% | -158.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 66.67% | -200.00% | -- |
| Cash from Financing | -56.46% | -47.52% | -14.69% | 30.77% | 55.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7,750.00% | -18.73% | -938.03% | 49.70% | -101.51% |